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2008-2009 Influenza Season 
Week 37 ending September 19, 2009 
All data are preliminary and may change as more reports are received. 
 
Synopsis:  During week 37 (September 13-19, 2009), influenza activity increased in the U.S. 
o 2,326 (23.9%) specimens tested by U.S. World Health Organization (WHO) and National 
Respiratory and Enteric Virus Surveillance System (NREVSS) collaborating laboratories and 
reported to CDC/Influenza Division were positive for influenza. 
o 99% of all subtyped influenza A viruses being reported to CDC were 2009 influenza A 
(H1N1) viruses. 
o The proportion of deaths attributed to pneumonia and influenza (P&I) was below the 
epidemic threshold.  
o Three influenza-associated pediatric deaths were reported and all three were associated 
with 2009 influenza A (H1N1) virus infection. 
o The proportion of outpatient visits for influenza-like illness (ILI) was above the national 
baseline. Regions 2 through10 reported ILI above region-specific baseline levels; only 
Region 1 was below its’ region-specific baseline. 
o Twenty-six states reported geographically widespread influenza activity, 11 states reported 
regional influenza activity, 12 states, the District of Columbia, and Puerto Rico reported local 
influenza activity, one state and Guam reported sporadic influenza activity, and the U.S. 
Virgin Islands did not report. 
o The 2009-10 influenza season officially begins October 4, 2009. 
 
National and Regional Summary of Select Surveillance Components 
 Data for current week Data cumulative for the 2008-09 season 
HHS 
Surveillance 
Regions* 
Out-
patient 
ILI† 
% 
positive 
for flu‡ 
Number of  
jurisdiction
s reporting 
regional or 
widespread 
activity§  
A (H1) A (H3) 2009 A (H1N1) 
A  
(unable 
to sub-
type)¥ 
A 
(Subty-
ping not 
perfor-
med) 
B  Pediatric Deaths 
Nation Elevated 23.9% 37 of 54 8,240 4,363 46,329 1,325 23,056 10,782 117 
Region 1 Normal 4.2% 2 of 6 584 304 3,041 13 1,711 815 4 
Region 2 Elevated 3.7% 1 of 4 290 228 1,829 21 2,398 713 20 
Region 3 Elevated 15.1% 5 of 6 1,250 222 4,846 20 1,069 1,363 10 
Region 4 Elevated 24.2% 8 of 8 1,078 784 8,719 105 4,644 1,318 13 
Region 5 Elevated 20.2% 5 of 6 1,593 213 8,903 214 1,009 1,383 18 
Region 6 Elevated 25.9% 5 of 5 830 312 4,595 14 6,108 2,669 18 
Region 7 Elevated 21.0% 3 of 4 488 84 1,448 570 660 519 1 
Region 8 Elevated 17.1% 3 of 6 541 219 1,989 80 2,231 506 9 
Region 9 Elevated 37.2% 3 of 5 1,200 1,680 7,937 74 2,687 810 21 
Region 10 Elevated 27.6% 2 of 4 386 317 3,022 214 539 686 3 
* HHS regions (Region I: CT, ME, MA, NH, RI, VT; Region II: NJ, NY, Puerto Rico, US Virgin Islands; Region III: DE, DC, MD, PA, VA, WV; Region IV: AL, FL, GA, KY, MS, NC, 
SC, TN; Region V: IL, IN, MI, MN, OH, WI; Region VI: AR, LA, NM, OK, TX; Region VII: IA, KS, MO, NE; Region VIII: CO, MT, ND, SD, UT, WY; Region IX: AZ, CA, Guam, HI, 
NV; and Region X: AK, ID, OR, WA). 
† Elevated means the % of visits for ILI is at or above the national or region-specific baseline. 
‡ National data are for current week; regional data are for the most recent three weeks. 
§ Includes all 50 states, the District of Columbia, Guam, Puerto Rico, and U.S. Virgin Islands. 
¥ The majority of influenza A viruses that cannot be sub-typed as seasonal influenza viruses are 2009 A (H1N1) influenza viruses upon further testing. 
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U.S. Virologic Surveillance:  WHO and NREVSS collaborating laboratories located in all 50 states 
and Washington D.C. report to CDC the number of respiratory specimens tested for influenza and 
the number positive by influenza type and subtype. The results of tests performed during the 
current week are summarized in the table below. 
 
 
 Week 37 
No. of specimens tested 9,744 
No. of positive specimens (%) 2,326 (24.9%) 
Positive specimens by type/subtype  
Influenza A 2,324 (99.9%) 
          A (2009 H1N1)   1,395 (60.0%)  
          A (subtyping not performed)          907 (39.0%)
          A (unable to subtype)  17 (0.7%)  
          A (H3)                1 (0.1%)  
          A (H1) 4 (0.2%)
Influenza B 2 (0.1%) 
 
During week 37, seasonal influenza A (H1), A (H3) and influenza B viruses co-circulated at low 
levels with 2009 influenza A (H1N1) viruses.  Ninety-nine percent of all subtyped influenza A 
viruses reported to CDC this week were 2009 influenza A (H1N1) viruses. 
 
Influenza Positive Tests Reported to CDC by U.S. WHO/NREVSS 
Collaborating Laboratories, National Summary, 2008-09 
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Pneumonia and Influenza Hospitalization and Death Tracking: This new system was 
implemented on August 30, 2009, and replaces the weekly report of laboratory confirmed 2009 
H1N1-related hospitalizations and deaths.  Jurisdictions can now report to CDC either laboratory 
confirmed or pneumonia and influenza syndromic-based counts of hospitalizations and deaths 
resulting from all types or subtypes of influenza, not just those from 2009 H1N1 influenza virus.  To 
allow jurisdictions to implement the new case definition, counts were reset to zero on August 30, 
2009.  From August 30-September 19, 2009, 10,082 hospitalizations and 936 deaths associated 
with influenza virus infection or based on syndromic surveillance for influenza and pneumonia, were 
reported to CDC. This is the third week of data from this new system and reflects reports by 52 
jurisdictions.  CDC will continue to use its traditional surveillance systems to track the progress of 
the remainder of the 2008-09 season, and for the 2009-10 influenza season, which officially begins 
October 4, 2009.  
Antigenic Characterization:  CDC has antigenically characterized 2,191 seasonal human 
influenza viruses [1,213 influenza A (H1), 264 influenza A (H3) and 714 influenza B viruses] 
collected by U.S. laboratories since October 1, 2008, and 716 2009 influenza A (H1N1) viruses. 
1,186 (98%) of 1,213 seasonal influenza A (H1) viruses tested are related to the influenza A (H1N1) 
component of the 2009-10 Northern Hemisphere influenza vaccine (A/Brisbane/59/2007) and 27 
(2%) showed reduced titers with antisera produced against A/Brisbane/59/2007.  Two hundred 
twenty-nine (87%) of 264 influenza A (H3N2) viruses tested are related to the influenza A (H3N2) 
2009-10 vaccine component (A/Brisbane/10/2007) and 35 viruses (13%) tested showed reduced 
titers with antisera produced against A/Brisbane/10/2007.  
All 716 2009 influenza A (H1N1) viruses are related to the A/California/07/2009 (H1N1)pdm  
reference virus selected by WHO as the component of the 2009 influenza A (H1N1) vaccine. 
Influenza B viruses currently circulating can be divided into two distinct lineages represented by the 
B/Yamagata/16/88 and B/Victoria/02/87 viruses. Six hundred thirty-eight (89%) of 714 influenza B 
viruses tested belong to the B/Victoria lineage, and of these, 630 (99%) are related to the influenza 
vaccine component for the 2009-10 Northern Hemisphere influenza vaccine (B/Brisbane/60/2008), 
and the remaining eight (1%) showed reduced titers with antisera produced against 
B/Brisbane/60/2008.  Seventy-six (11%) influenza B viruses tested belong to the B/Yamagata 
lineage.  
Data on antigenic characterization should be interpreted with caution given that antigenic 
characterization data are based on hemagglutination inhibition (HI) testing using a panel of 
reference ferret antisera, and results may not correlate with clinical protection against circulating 
viruses provided by influenza vaccination. 
Annual influenza vaccination is expected to provide the best protection against those virus 
strains that are related to the vaccine strains, but limited to no protection may be expected when the 
vaccine and circulating virus strains are so different as to be from different lineages, as is seen with 
the two lineages of influenza B viruses.  Antigenic characterization of 2009 influenza A (H1N1) 
viruses indicates that these viruses are antigenically and genetically unrelated to seasonal influenza 
A (H1N1) viruses, suggesting that little to no protection would be expected from vaccination with 
seasonal influenza vaccine. 
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Antiviral Resistance: Since October 1, 2008, 1,148 seasonal influenza A (H1N1), 261 influenza A 
(H3N2), 654 influenza B, and 705 2009 influenza A (H1N1) virus isolates have been tested for 
resistance to the neuraminidase inhibitors (oseltamivir and zanamivir).  In addition, 973 2009 
influenza A (H1N1) original clinical samples were tested for a single known mutation in the virus 
that confers oseltamivir resistance.  Also, 1,153 seasonal influenza A (H1N1), 261 influenza A 
(H3N2), and 526 2009 influenza A (H1N1) viruses have been tested for resistance to the 
adamantanes (amantadine and rimantadine).  The results of antiviral resistance testing performed 
on these viruses are summarized in the table below.  Additional laboratories perform antiviral 
testing and report their results to CDC.  Two additional oseltamivir resistant 2009 influenza A 
(H1N1) viruses have been identified by these laboratories.   
 
Resistant 
Viruses, 
Number (%) 
Resistant 
Viruses, 
Number (%) 
Resistant 
Viruses, 
Number (%)  Viruses tested (n) 
Oseltamivir 
Viruses 
tested (n) 
Zanamivir 
Viruses 
tested (n) 
Adamantanes 
Seasonal 
Influenza A 
(H1N1) 
1,148 1,143 (99.6%) 1,148 0 (0) 1,153 6 (0.5%) 
Influenza A 
(H3N2) 261 0 (0) 261 0 (0) 261 261 (100%) 
Influenza B 654 0 (0) 654 0 (0) N/A* N/A* 
2009 
Influenza A  
(H1N1) 
1,678 9†‡ (0.6) 705 0 (0) 526 526 (100%) 
*The adamantanes (amantadine and rimantadine) are not effective against influenza B viruses. 
†Two screening tools were used to determine oseltamivir resistance: sequence analysis of viral genes and a neuraminidase inhibition 
assay. 
‡ Additional laboratories perform antiviral resistance testing and report their results to CDC.  Two additional oseltamivir resistant 2009 
influenza A (H1N1) viruses have been identified by these laboratories, bringing the total number to 11. 
 
2009 influenza A (H1N1) viruses were tested for oseltamivir resistance by a neuraminidase 
inhibition assay and/or detection of genetic sequence mutation, depending on the type of specimen 
tested.  Original clinical samples were examined for a single known mutation in the virus that 
confers oseltamivir resistance in currently circulating seasonal influenza A (H1N1) viruses, while 
influenza virus isolates were tested using a neuraminidase inhibition assay that determines the 
presence or absence of neuraminidase inhibitor resistance, followed by the neuraminidase gene 
sequence analysis of resistant viruses.   
 
The majority of 2009 influenza A (H1N1) viruses are susceptible to the neuraminidase inhibitor 
antiviral medication oseltamivir; however, rare sporadic cases of oseltamivir resistant 2009 
influenza A (H1N1) viruses have been detected worldwide, including 11 cases in the United States.  
All tested viruses retain their sensitivity to the other neuraminidase inhibitor: zanamivir.  Ten 
patients (including the nine viruses detected at CDC and one identified by an additional laboratory) 
had documented exposure to oseltamivir through either treatment or chemoprophylaxis, and the 
remaining patient is currently under investigation to determine exposure to oseltamivir.  Occasional 
development of oseltamivir resistance during treatment or prophylaxis is not unexpected.  
Enhanced surveillance is expected to detect additional cases of oseltamivir resistant 2009 influenza 
A (H1N1) viruses, and such cases will be investigated to assess the spread of resistant strains in 
the community.  To prevent the spread of antiviral resistant virus strains, CDC reminds clinicians 
and the public of the need to continue hand and cough hygiene measures for the duration of any 
symptoms of influenza (http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5832a3.htm).  
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Additional information on antiviral recommendations for treatment and chemoprophylaxis of 
influenza virus infection is available at http://www.cdc.gov/h1n1flu/recommendations.htm.  Antiviral 
treatment with oseltamivir or zanamivir is recommended for all patients with confirmed or suspected 
influenza virus infection who are hospitalized or who are at higher risk for influenza complications. 
 
Three seasonal influenza A (H1N1) viruses collected between February 8 and May 11, 2009, were 
found to be resistant to both oseltamivir and the adamantanes (amantadine and rimantadine).  All 
seasonal influenza A (H1N1) viruses tested retain their sensitivity to zanamivir.  The three dually-
resistant viruses represent less than 1% of all seasonal influenza A (H1N1) viruses tested during 
the 2008-09 influenza season, and as a result, no changes to the influenza antiviral treatment or 
prophylaxis recommendations will be made at this time.  CDC will continue to monitor trends in 
antiviral resistance over the summer and throughout the upcoming 2009-10 influenza season.   
 
 
Pneumonia and Influenza (P&I) Mortality Surveillance:  During week 37, 6.1% of all deaths 
reported through the 122-Cities Mortality Reporting System were due to P&I. This percentage was 
below the epidemic threshold of 6.3% for week 37. 
 
Pneumonia and Influenza Mortality for 122 U.S. Cities 
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Influenza-Associated Pediatric Mortality:  Three influenza-associated pediatric deaths were 
reported to CDC during week 37 (Texas [2] and Virginia).  These deaths were associated with 2009 
influenza A (H1N1) virus infection, and occurred between August 30 and September 19, 2009.  
Since September 28, 2008, CDC has received 117 reports of influenza-associated pediatric deaths 
that occurred during the current influenza season (25 deaths in children less than 2 years, 12 
deaths in children 2-4 years, 35 deaths in children 5-11 years, and 45 deaths in individuals 12-17 
years). Forty-nine of the 117 deaths were due to 2009 influenza A (H1N1) virus infections, and four 
of these have occurred since August 30, 2009.   
 
Of the 50 children who had specimens collected for bacterial culture from normally sterile sites, 19 
(38.0%) were positive; Staphylococcus aureus was identified in 13 (68.4%) of the 19 children.  Six 
of the S. aureus isolates were sensitive to methicillin and seven were methicillin resistant.  
Seventeen (89.5%) of the 19 children with bacterial coinfections were five years of age or older and 
12 (63.2%) of the 19 children were 12 years of age or older.  Nineteen (38.8%) of the 49 children 
with confirmed 2009 influenza A (H1N1) infection had a specimen collected from a normally sterile 
site; five (26.3%) of the 19 children had a positive bacterial culture (methicillin sensitive S. aureus 
[2], methicillin resistant S. aureus [2], and Streptococcus constellatus).  
 
Number of Influenza-Associated Pediatric Deaths by Week of Death: 
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Influenza-Associated Hospitalizations:  Laboratory-confirmed influenza-associated 
hospitalizations are monitored through the Emerging Infections Program (EIP), a population-based 
surveillance network. 
 
During April 15, 2009 – September 19, 2009, the following preliminary laboratory-confirmed overall 
influenza associated hospitalization rates were reported by the EIP (rates include influenza A, 
influenza B, and 2009 influenza A (H1N1)): 
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Rates for children aged 0-23 months, 2-4 years, and 5-17 years were 2.6, 1.1, and 0.9 per 10,000, 
respectively.  Rates for adults aged 18-49 years, 50-64 years, and ≥ 65 years, the overall flu rates 
were 0.6, 0.6, and 0.5 per 10,000, respectively. 
 
EIP Influenza Laboratory-Confirmed Cumulative Hospitalization Rates, 
Spring/Summer 2009 
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*This value represents an age group-specific average influenza rate from October 1 to April 30 from the 2005-
06, 2006-07, and 2007-08 influenza seasons. 
**Note: The scales for the 0-23 month and the ≥65 year age groups differ from other age groups. 
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Outpatient Illness Surveillance: Nationwide during week 37, 4.6% of patient visits reported 
through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to 
influenza-like illness (ILI).  This percentage is above the national baseline of 2.4%. 
 
Percentage of Visits for Influenza-like Illness (ILI) Reported by  
the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), 
National Summary, 2008-09 and Previous Two Seasons 
*There was no week 53 during the 2006-07 and 2007-08 seasons, therefore the week 53 data point for those seasons is an average of weeks 52 and 1.
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On a regional level, the percentage of outpatient visits for ILI ranged from 1.4% to 8.9%, and 
decreased in four of the 10 surveillance regions. Nine regions (Regions 2 through 10) reported a 
proportion of outpatient visits for ILI above region-specific baseline levels, while Region 1 reported a 
percentage of visits for ILI below its’ region-specific baseline.   
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Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists:  The 
influenza activity reported by state and territorial epidemiologists indicates geographic spread of 
both seasonal influenza and 2009 influenza A (H1N1) viruses and does not measure the severity of 
influenza activity. 
 
During week 37, the following influenza activity was reported: 
 Widespread influenza activity was reported by 26 states (Alabama, Alaska, Arizona, 
Arkansas, California, Colorado, Delaware, Florida, Georgia, Illinois, Kansas, Kentucky, 
Louisiana, Maryland, Minnesota, Mississippi, Nevada, New Mexico, North Carolina, 
Oklahoma, Pennsylvania, South Carolina, Texas, Tennessee, Virginia, and Washington). 
 Regional influenza activity was reported by 11 states (Indiana, Iowa, Maine, Montana, 
Nebraska, New Hampshire, New Jersey, Ohio, South Dakota, West Virginia, and 
Wisconsin). 
 Local influenza activity was reported by the District of Columbia, Puerto Rico, and 12 states 
(Connecticut, Hawaii, Idaho, Massachusetts, Michigan, Missouri, New York, North Dakota, 
Oregon, Rhode Island, Utah, and Wyoming). 
 Sporadic activity was reported by Guam and one state (Vermont). 
 The U.S. Virgin Islands did not report. 
 
A description of surveillance methods is available at: http://www.cdc.gov/flu/weekly/fluactivity.htm 
 
Report prepared: September 25, 2009. 
  
 
